Search tips
Search criteria 


Logo of springeropenLink to Publisher's site
Journal of Neuro-Oncology
J Neurooncol. 2007 April; 82(2): 163–164.
Published online 2007 January 26. doi:  10.1007/s11060-006-9321-z
PMCID: PMC1915654

Hemangioblastomatosis in a patient with von Hippel-Lindau disease

Case presentation

A woman developed a cerebellar hemangioblastoma in 1991 at the age of 17 and von Hippel-Lindau disease was diagnosed. She underwent five craniotomies for recurrent hemangioblastoma. In 2001 she had a laminectomy for an intramedullar hemangioblastoma at C2-C3 level. In 2004 a renal cell carcinoma was found and a partial nephrectomy was performed. A few weeks after her last craniotomy in July 2005 she developed progressive right hemisensory disturbances and sensory ataxia. Spinal MRI showed leptomeningeal contrast enhancement around the entire spinal cord (see Figure). The sensory ataxia progressed and she got tetraparesis, most severe proximally in her arms, especially myotome C4. Although hemangioblastoma are not very radiosensitive, radiotherapy was started because of the rapid clinical deterioration. High-dose total neuraxis radiotherapy was considered to toxic. It was judged that most of her clinical complaints could be attributed to the cervical spine. Also the MRI showed the most severe lesions at the cervical region. Therefore she was treated from C1 to Th1 (30 × 1.8 Gy) combined with dexamethasone (2 × 8 mg). During radiotherapy she developed also symptoms outside the radiotherapy field (thoracal radiculopathy).

figure 11060_2006_9321_Fig1_HTML

As the main problem in VHL is uncontrolled angiogenesis by overexpressing VEGF and VEGF receptors, Thalidomide (400 mg, later 600 mg) was added. Thalidomide inhibits angiogenesis induced by VEGF [1]. Despite the treatment she developed a total tetraplegia and died 3 months after diagnosis as a result of respiratory failure.

This syndrome appears to result from delayed growth of subarachnoid tumor cells disseminated by surgery. Hemangioblastomatosis is also seen in hemangioblastoma patients without von Hippel-Lindau disease and it is thought that additional genes are likely to be the source of this malignant behaviour [2].


1. Piribauer M, Czech T, Dieckmann K et al. (2004) Stabilization of a progressive hemangioblastoma under treatment with thalidomide. J Neurooncol 66:295–299 [PubMed]
2. Weil RJ, Vortmeyer AO, Zhuang Z et al. (2002) Clinical and molecular analysis of disseminated hemangioblastomatosis of the central nervous system in patients without von Hippel-Lindau disease. J Neurosurg 96:775–787 [PubMed]

Articles from Springer Open Choice are provided here courtesy of Springer